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Only half a century after the landmark
discovery of the double helix structure of
DNA, the human genome was sequenced
and a new era of biomedical research was
ushered in [1]. Parallel advances in
comparative genomics, genetics, high-
throughput biochemical techniques, and
bioinformatics have provided researchers
in wealthy nations with a repertoire of
tools to analyze the sequence and func-
tions of organisms at an unprecedented
pace and level of detail. Since the
beginning of the genomics era [2,3],
however, it has been evident that research-
ers in many developing countries will not
be participating fully in genomics research,
mainly because of their technological
isolation and their limited resources and
capacity for genomics research combined
with the urgency of many other health
priorities. To share the benefits of this
technology equitably worldwide, some
have advocated that developed and devel-
oping countries alike should participate in
genomics research to prevent widening of
the already large gap in global health
resources [4]. As most of the funding that
has fueled the rapid advance of the field
comes from developed country govern-
ments, private initiatives, and industry,
however, not much has been done to
enable poorer countries to participate as
equals in genomics research. Developing
countries that are not directly participating
in a genomics initiative can, nonetheless,
gain from the discoveries of this field in a
number of ways, as detailed below. It
remains to be seen, however, how the
developing world will specifically benefit
from the refined genetic information and
the drugs and vaccines produced as a result
of genomics initiatives. Information ex-
change and translation of knowledge must
be carried out continually through fora
accessible to researchers in developing
countries. ‘‘North–South’’ collaborations—
starting with capacity building in genomics
research—need to be fostered so that
countries that are currently excluded from
the genomics revolution find an entry point
for participation. ‘‘South–South’’ collabo-
rations must be encouraged to allow
countries with limited resources to pool
their human and financial capital, learn
from each other’s experience, and share in
the benefits of genomics. Ensuring that the
benefits of genomics-based medicine are
shared by developing countries involves
their inclusion in the discussion of ethical,
legal, social, economic, and sovereignty
issues (Box 1).
Initiatives in the Developing
World
In the developing world, the link between
human genomics and infectious disease is
particularly important. The influence of
host genes on the differential susceptibility
of individuals or populations to infection
and the evolutionary influence of pathogens
on the genetic composition of populations
by selecting for resistant individuals through
coevolution can be now dissected in more
detail with genomics. An array of host–
pathogen interactions are associated with
particular human genes and loci, as best
illustrated by the relationship of the malaria
pathogen with host genetic evolution. As
genetic information about larger popula-
tions becomes increasingly available, it
is important to disseminate information
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Summary Points
N Researchers in most developing
countries lack the technology,
resources, and capacity to partic-
ipate fully in genomics research.
N Information exchange and knowl-
edgetranslationmustbecarriedout
continually through ‘‘North–South’’
collaborations, starting with capaci-
ty building in genomics research;
‘‘South–South’’ collaborations must
be encouraged to allow countries
with limited resources to pool their
human and financial capital and
share in the benefits of genomics.
N Several emerging countries have
made significant progress in the
past decade by sequencing the
genomes of organisms with little
economic value in the developed
world but of great local relevance.
N Molecular diagnostics and molec-
ular epidemiology are the first
frontier of genomics, with acces-
sible tools that can be applied in
resource-limited settings.
N Developing countries entering the
genomics era should start by es-
tablishing their priorities and enact-
ing appropriate legislation before
embarking on large-scale projects.
N Access to training and capacity
building of human resources in
bioinformaticsanddatamining are
crucial in the developing world.
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devise intervention strategies for at-risk
populations worldwide [5].
Because science and technology are
increasingly recognized as vital compo-
nents for national development, emerging
economies and some developing countries
are building their infrastructures to pro-
mote local innovation and to retain the
value of their human, plant, and microbial
genomic diversity and research. India,
Thailand, South Africa, Indonesia, Brazil,
and Mexico, for example, have devoted
considerable resources to large-scale popu-
lation genotyping projects that explore
human genetic variation. The Institute for
Genomic Medicine (INMEGEN) initiative
in Mexico is the largest and most compre-
hensive, with a broad strategy for incorpo-
rating genomics into health care that
includes infrastructure, strategic public–
private partnerships, research and develop-
ment in genomics relevant to local health
problems, capacity building, and bioethics
policy making [6,7]. Although it is unclear
how Mexico will make the transition from
early-phase investment to translation of
knowledge into products and services with
health and economic impacts, the country
is taking important steps to address the
challengesitandotheremergingeconomies
face, such as the shortage of trained
professionals and the ability to retain local
talent. For example, the National Council
for Science and Technology (CONICYT)
is making efforts to engage the Mexican
scientific diaspora with expertise in geno-
mics by offering repatriation packages tied
to jobs at universities and research insti-
tutes, an approach that is also being
adopted by Brazil.
Brazil’s Foundation for Research Sup-
port in Sao Paolo (FAPESP) genomics
initiative is also considered a political and
scientific achievement. Key to its success
has been early investment in training
young scientists by sponsoring scholarships
abroad in areas related to genomics in
which Brazil lacks expertise. To avoid
brain drain, beneficiaries are required to
return to Brazil for at least four years and
must have a committed teaching position
at a local university before they leave. One
important principle of Brazil’s genomics
initiative is that the projects are relevant to
Brazil and the rest of the developing world
but are low on the list of priorities of the
US and Europe, thus providing both an
important contribution to genomics and a
benefit to Brazil’s economy and scientific
endeavor [8]. FAPESP is in the process of
sequencing the genes of the parasite that
causes schistosomiasis, a disease that
afflicts millions in Brazil. Another example
in Brazil is the government-funded con-
sortium Organization for Nucleotide Se-
quencing and Analysis (ONSA), formed to
sequence and analyze the genome of the
plant pathogen Xylella, which infects
orange trees and has great economic
impact [9]. This effort led to additional
genomics projects on vectors of pathogens
that cause major public health problems in
Brazil, such as the sandfly Lutzomyia long-
ipalpis, which transmits Leishmania spp.,
and the Triatominae bug species, which
are vectors of Trypanosoma cruzi [10].
The impact of genomics on the devel-
oping world is also illustrated by multina-
tional initiatives such as the one funded by
the US National Institutes of Health
(NIH), the UK’s Wellcome Trust, and
private and public institutes in the US and
Europe in collaboration with research
centers in Brazil, Argentina, Venezuela
and Singapore to sequence the genomes of
the parasites T. brucei, T. cruzi and
Leishmania major, which cause the deadly
insect-borne diseases African sleeping sick-
ness, Chagas disease, and leishmaniasis,
respectively [11–13]. The potential new
drug targets identified by these initiatives
have great relevance in over 100 develop-
ing countries where the diseases take a
significant toll on the economy and the
quality of life of their citizens. Similar
initiatives have resulted in sequencing of
other pathogens important to medicine
and agriculture. The data from these
projects are usually freely available online
for data mining and for bioinformatics
analysis at remote locations, as most
researchers follow the recommendation
set by the Bermuda Accord to make
DNA sequences (especially human) freely
and openly available without delay [14].
Resource-limited countries can enter
the genomics era by creating partnerships
and regional centers for technology and
resources [15]. For example, DNA se-
quencing technology, still unaffordable for
many researchers and public laboratories
because of low-use volume and high costs
of equipment, reagents, and maintenance,
can be affordable if a regional center
provides services to a pool of laboratories
and researchers within a country or
geographical region. As an illustration,
using Brazilian infrastructure, Peru ´ and
Chile joined the global potato sequencing
consortium, which will sequence different
varieties of this important agricultural
species [16]. Brazil has also generated
several open-source bioinformatics tools
for the annotation of bacterial and proto-
zoan genomes that can be used by any
researcher worldwide [17]. In Africa, the
Center for Training in Functional Geno-
mics of Insect Vectors of Human Disease
(AFRO VECTGEN) was initiated by
TDR (Special Programme in Research
and Training in Tropical Diseases) at the
World Health Organization (WHO) and
the Department of Medical Entomology
and Vector Ecology of the Malaria
Research and Training Center in Mali to
train young scientists in functional geno-
mics who will ultimately use genome
sequence data for research on insect
vectors of human disease. The program
triggers collaborative research with neigh-
boring nations and the vector biology
network in Mali, which was built around
research grants funded by the US NIH
and TDR/WHO [18]. The Malaria
Genomic Epidemiology Network (Malar-
iaGEN) uses a consortial approach that
brings together researchers from 21 coun-
tries to overcome scientific, ethical, and
practical challenges to conducting large-
scale studies of genomic variation that
could assist efforts in the fight against
malaria [19]. Successful ‘‘North–South’’
partnerships that help scientists bridge
the genomic gap usually involve a project
of mutual interest. An example is the
Box 1. Societal and Ethical Issues in Genomics to Be Discussed
with Full Participation of All Nations
N Issues of confidentiality, stigmatization, discrimination, and misuse of genetic
information
N Dangers of a reductionist approach to health issues based only on genetic
information that ignores multifactorial determinants
N Issues about intellectual property rights associated with the patentability of
DNA sequences, the applications derived from them, and the implications for
developing countries [45]
N The potential exploitation of developing-country populations by creating
genetic databases for a price [46]
N The potential risk of breeding human beings by design [47]
N Issues about informed consent, standard of care, and availability and pricing of
new drugs and vaccines being tested in developing countries [48]
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stock Research Institute (ILRI) in Nairobi
and The Institute for Genome Research
(TIGR; now the J. Craig Ventner Insti-
tute) to sequence and annotate the genome
of Theileria parva, a cattle parasite that
causes important economic losses to small
farmers in Africa and elsewhere [20]. This
effort has generated local human resources
in genomics and infrastructure for the
future.
Application of Molecular,
Genetic, and Genomic Tools
with Limited Resources
Although the genomics initiatives de-
scribed above challenge the notion that
developing countries must wait to import
advances in science and technology that
emerge from the developed world, poorer
developing countries still do not have the
resources to develop their own genomic
projects on a large scale. However,
implementing simpler molecular genetic
approaches to solve health problems is
very feasible in resource-limited settings.
The decades preceding the human and
microbial genome initiatives were high-
lighted by important developments in
molecular and genetic methods applied
to infectious diseases. These developments
were enabled by increasingly available
genetic information about many patho-
gens and their vectors and by molecular
tools such as PCR and powerful sequenc-
ing technologies, which permitted rapid
advances that were successfully introduced
into the developing world with little delay.
Molecular tools for diagnosis have
gained a ready foothold because many
poor countries do not have the facilities for
traditional diagnosis and surveillance.
Thus, diagnosis often relies on clinical
observations or requires that a sample be
sent out to foreign agencies such as the US
Centers for Disease Control and Preven-
tion (CDC) for confirmation. In addition,
even when available, classic techniques
based on serological, microscopic, and
culture-based methods are often lengthy,
of only moderate sensitivity, and not
highly discriminatory at the level of species
subtype or strain. By adapting DNA
technologies to the existing infrastructure,
using home-grown solutions to reduce
their cost, and applying them to solve
local health problems, molecular ap-
proaches to detect and type infectious
agents on-site offer real value [21]. Fos-
tering appropriate technology transfer and
capacity-building in the ‘‘South’’ enables
public health laboratories and research
groups in less scientifically developed
countries to participate in global genomics
by contributing their findings and sharing
their expertise with their peers [22,23].
For example, we and others adapted PCR-
based molecular diagnostic techniques for
infectious diseases such as leishmaniasis
and dengue for cost-effective application
in laboratories with minimum infrastruc-
ture and basic technical expertise, which
are now fully validated and used routinely
throughout Latin America [21,24–30].
This approach relies on understanding
the principles of the technologies, decon-
structing them into their basic compo-
nents, and rebuilding them on-site [21].
Another area where molecular tools have
demonstrated their utility in resource-poor
settings is in detecting drug resistance in a
variety of pathogens. This has been facili-
tated in large part by successful ‘‘North–
South’’ partnerships that have served to
train scientists in developing countries in the
use, implementation, and interpretation of
modern molecular methods applied to
emerging drug resistance (see [31]). This
approach has been particularly successful
with certain diseases, such as malaria, HIV/
AIDS, tuberculosis, and drug-resistant bac-
terial infections (both nosocomial and com-
munity-based). Unfortunately, most studies
of drug-resistant pathogens are performed
independentlyof one another, sodata on the
prevalence of resistance markers is scattered
in disparate databases or in unpublished
studies without links to clinical, laboratory,
and pharmacokinetic data needed to relate
the genetic information to relevant pheno-
types. To enable molecular markers of
malaria drug resistance to realize their
potential as public health tools, the World-
wide Malaria Resistance Network (WARN)
database is being created with the dual goals
of improving treatment of malaria by
informed drug selection and use and
providing a prompt warning when treat-
ment protocols need to be changed [32,33].
By accelerating the identification and vali-
dation of markers for resistance to combi-
nation therapies, this global database should
help prolong the useful therapeutic lives of
important new drugs.
The ultimate power of genetic tools in
resource-limited settings is evident in the
field of molecular epidemiology, where
genetic information about the host or
infectious agent is analyzed together with
clinical and epidemiological data to derive
and implement appropriate interventions.
For example, molecular tools based on
limited sequence information, such as
molecular fingerprinting of a polymorphic
marker, have made important contributions
to strengthening control of tuberculosis in
bothdevelopedand developingcountriesby
enabling analysis of transmission patterns,
helping identify phenotypic variation
among strains, and facilitating evaluation
of the global distribution, relative transmis-
sibility, virulence, and immunogenicity of
different lineages of M. tuberculosis [34–38].
Bacterial infections, food-borne outbreaks,
and viral infections in developing countries,
including the recent H1N1 influenza pan-
demic, are monitored using similar typing
methodologies [39–41]. Molecular tools
permit a refined case definition and thus
have tremendous potential for decision-
making support and informing targeted
public health interventions in countries with
high burdens of disease and limited tech-
nological capabilities and resources.
The trend to move beyond genetic
marker analysis to full genome sequencing
is growing, as complete genome data can
provide a wealth of information about
etiologic agents of disease that was previ-
ously unknown. Full-genome approaches
are not always necessary, however. In
molecular epidemiology of infectious dis-
eases, nucleic acid fingerprinting can
provide enough answers to important
epidemiological questions to allow critical
interventions to be designed (see above). In
fact, too much genetic information, in
some instances, can obscure the picture, as
several closely related pathogenic variants
might coexist in one individual or one
outbreak that differ by only a few
nucleotides but that nonetheless belong
to the same strain or subtype, complicating
the interpretation of results [42].
The relatively rapid transfer of DNA
technology from developed to developing
countries is an excellent example of what
can be done by forging strong relation-
ships between universities and research
groups and public-health laboratories
across the world. The validity of adapting
these technologies relies on links with
epidemiological data and translation into
local public health interventions.
Setting Priorities
General international ethical and scien-
tific guidelines for genomics have been
created and are being adapted by nations
participating in the field as it evolves.
Governments and regulatory agencies in
the ‘‘North’’ have prepared for the
eventual implementation of genomics-
based medicine in their respective coun-
tries. A critical problem faced by develop-
ing countries is the lack of national
guidelines for genomics research and its
ethical ramifications. Thus, a priority to be
set by countries in the early steps of
genomic applications is to draw up the
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mics and to generate procedures for
implementation. Creating the necessary
communication channels between re-
searchers, social scientists, policy makers,
and civil society organizations is also a
critical step. Other key challenges facing
emerging genomics researchers include
proper informed consent and privacy
protocols for research participants, pro-
tecting them against the potential discrim-
ination that might emerge from genetic
information and ensuring that any benefit
that comes to fruition from the research
reaches them. In parallel, capacity build-
ing of scientists in clinical research and of
ethics committees in these issues is essen-
tial. Past experience with ‘‘safari research’’
in which biological samples are taken out-
of-country for research that does not
benefit local populations have prompted
countries such as Mexico, India, and
Brazil to draw up legislation governing
‘‘sovereignty’’ over genomics material and
data that restricts the export of biological
materials for studies abroad and prioritizes
national interests. Poorer countries cur-
rently lacking their own genomics initia-
tives could benefit from similar legislation
balancing the protection of ‘‘genomic
sovereignty’’ while fostering international
collaborations that bring much-needed
resources and increase local scientific
capacity. Beyond the improvement of their
basic genomics research capabilities, gov-
ernments should engage their relevant
ministries to develop a plan to integrate
genetic and genomics products (including
diagnostics, vaccines, therapies, and oth-
ers), within the health system and public
health programs with emphasis on acces-
sibility and equity to improve health for
all. A good example of priority setting in
genomics is Mexico’s national genomics
program over the last 15 years (see Box 2).
Sharing Know-How
To strengthen genomics globally, the
tools necessary for analysis of genomics
data are urgently needed in developing
countries, where they are currently under-
utilized [43]. A problem with genomics is
that much of the advanced knowledge is
concentrated in individuals and a few
research centers and companies rather
than in textbooks or academia, restricting
dissemination even though massive
amounts of genomic data and software
are openly accessible through the Internet.
A conscious effort on the part of developed
nations to transfer their knowledge of the
use and analysis of genomic databases
needs to be encouraged to help developing
countries manage their own specific data
on indigenous biological species, local
epidemiology and infectious diseases, bio-
diversity, and other issues. Some successful
programs and initiatives include the Well-
come Trust Sanger Institute training
courses on bioinformatics and genomic
analysis, the Sustainable Sciences Insti-
tute–Broad Institute bioinformatics work-
shops (Figure 1), and the TDR/WHO-
South African Bioinformatics Institute
(SANBI) regional training center. Online
training like the S-star alliance bioinfor-
matics courses and conferences such as the
African Bioinformatics Conference (Af-
bix’09) with remote participation are
becoming more widespread and are an
excellent option for countries with limited
resources. GARSA (Genomic Analysis
Resources for Sequence Annotation) is a
flexible Web-based system designed to
analyze genomic data in the context of a
data analysis pipeline. Hosted in Brazil,
this free system aims to facilitate the
analysis, integration, and presentation of
genomic information, concatenating sev-
eral bioinformatics tools and sequence
databases with a simple user interface
[44]. An alternative to on-site sequencing
is to partner with colleagues in more-
developed countries to have samples
processed abroad in sequencing centers.
This is possible only if local legislation
allows for export of biological samples,
and if true partnership and trust exist with
a colleague(s) in the developed country.
Challenges for the Future
As developing countries reevaluate their
role in the genomics era, they will continue
to explore the unique opportunities that
arise from the vast natural and genomic
diversity that they embody. As exemplified
by the successes in Brazil, Mexico, and
several African countries, it is possible to
turn challenges and problems such as
emerging and endemic infectious diseases
into opportunities for unique scientific and
economic growth. Access to sequencing
facilities, open-source databases, and har-
monized methodologies for genomic analy-
sis are essential for the future of genomics in
the developing world. However, unless a
more concerted effort is made to include
countries with limited scientific development
and resources, it is unlikely that they will
fully participate in genomics projects or use
the technologies available other than by
allowing their genetic material to be acces-
sible to others. As emerging countries set
their own priorities for genomics research
and take ownership of its results, the main
challenge across developing nations remains
accesstotraining and knowledge translation.
Human resources and local capacity in
genomics are thus central to development,
as countries with these skills could partici-
pate in the potential benefits of the field with
respect to health, food security, natural
resource management, and other critical
areas. ‘‘North–South’’ and ‘‘South–South’’
collaborations are a viable and extremely
rewarding way to increase the capacities of
developing countries to access genomic tools
to address unique problems considered of
little economic value outside these countries
but of tremendous importance to the
majority of the world’s population.
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Box 2. Building a Road toward Genomics: The Mexican
Experience 1995–2009 [7]
N Increases in investment in science and technology (S&T) from 0.35% to 0.43% of
the GNP and creation of national S&T legislation to increase regional funding
N Four-fold increase in number of students registered for doctoral-level programs
N Participation in international genomics efforts
N Creation of sequencing initiatives of organisms with local agricultural and
health relevance
N Creation of a Genomics Sciences degree and two scientific societies in
genomics
N Creation of the National Institute of Genetic Medicine (2004-INMEGEN) with
seed funding for modern infrastructure; a strategy for development that
includes country-wide strategic alliances; high-level research and academic
programs; ethical, legal, and social implications of genomic medicine; and
translation of the scientific knowledge into public goods
N Establishment of genomics research priorities based on most prevalent local
diseases
N Plans for creation of public–private partnerships to guarantee sustainability
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